Northwest Biotherapeutics, Inc. filed its 10-K on Feb 28, 2023 for the period ending Dec 31, 2022. In this report its auditor, Cherry Bekaert LLP - Cherry, Bekaert & Holland, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.453 USD | -3.51% | +7.86% | -35.38% |
May. 10 | Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 21 | Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors | CI |
1st Jan change | Capi. | |
---|---|---|
-35.38% | 576M | |
+15.85% | 121B | |
+18.91% | 112B | |
+4.43% | 22.57B | |
-18.63% | 20.82B | |
-13.76% | 16.3B | |
-16.61% | 16.19B | |
-43.53% | 16.17B | |
+1.75% | 13.17B | |
+28.07% | 11.11B |
- Stock Market
- Equities
- NWBO Stock
- News Northwest Biotherapeutics, Inc.
- Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt